(Reuters) -Clearwater Analytics has agreed to acquire rival Enfusion in a $1.5 billion cash-and-stock deal as the financial software maker looks to bolster its international presence and enter the hedge fund industry.

Enfusion shareholders will receive $5.85 in cash and $5.40 in Clearwater stock for each share, valuing the Chicago-based firm at $11.25 per share, the companies said on Monday.

The value is a 32% premium to its close on Sep. 19 when Reuters had exclusively reported that Enfusion was exploring options including a sale after receiving takeover interest from potential suitors, including private equity firms.

The company had previously in 2023 also fielded acquisition interest from several potential acquirers, including Francisco Partners, Vista Equity Partners and Irenic Capital Management.

Enfusion, primarily serving hedge funds, provides portfolio management and risk systems to investment funds, and expects a revenue of $201 million to $202 million in 2024.

Certain shareholders affiliated with investment firms FTV Management Company and ICONIQ Capital and Enfusion CEO Oleg Movchan, who collectively hold about 45% of voting power, have agreed to support the deal.

© Reuters. FILE PHOTO: Signage for Clearwater Analytics is seen at the New York Stock Exchange (NYSE) in Manhattan, New York City, U.S., September 24, 2021. REUTERS/Andrew Kelly/File Photo

J.P. Morgan Securities and Kirkland & Ellis advised Clearwater Analytics, while Goldman Sachs and Dechert advised Enfusion’s special committee. Goodwin Procter advised Enfusion.

The deal is expected to close in the second quarter of 2025.


Source link

Best Brokers

Unmatched trading fees, generous bonuses, top notch Regulation Frame.

T&Cs Apply

Risk disclosure: All investments involve a degree of risk of some kind. Trading financial derivative products comes with a high risk of losing money rapidly due to leverage.

Top-Tier Regulations. Unmatched Spreads and Commissions. Trading View is available.

T&Cs Apply

Financial Spread Trades and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84.7% of retail investor accounts lose money when trading CFDs with this provider.

Modern and Intuitive Interfaces, Solid Regulatory Frame, and excellent Trading Fees.

T&Cs Apply
Risk warning: Trading derivatives is highly speculative, carries an inherent risk of loss and is not suitable for all investors. Before trading, you are strongly advised to read and ensure that you understand the relevant risk disclosures and warnings.

Highly Regulated. Low Spreads and Commissions. Vast Account Options.

T&Cs Apply

Risk Warning: Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment.